Negev Capital primarily target companies with medications that are at early stage of clinical development.
Business Model:
Revenue: $0
Employees: 0-0
Address: PO Box 309
City: Grand Cayman
State: other
Zip: KY1-1104
Country: KY
Negev Capital is a psychedelic medical intervention investment fund with assets of USD$20+ million. We invest in drug discovery, with a focus on preclinical and/or Phase 1 stages of development. We aim to support those early stage companies in need of capital that promote the thoughtful, responsible, medical use of psychedelic medication for psychiatric disorders, and who have excellent management and science teams, and solid IP.
Contact Phone:
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
8/2021 | Beckley Psytech | Series B | 0 |
12/2022 | Gilgamesh Pharmaceuticals | Series B | 0 |
6/2021 | NanoPsy | Seed Round | 0 |
9/2021 | MycroDose Therapeutics | Seed Round | - |
9/2021 | Delix Therapeutics | Series A | 0 |
6/2021 | Ocean Bio | Pre Seed Round | 0 |
2/2022 | Mindstate Design Labs | Seed | 11.5M |
10/2022 | Psylo | Seed Round | 3.2M |
2/2022 | Mindstate Design Labs | Seed Round | 0 |
9/2021 | Delix Therapeutics | Series A | 0 |
9/2021 | MycroDose Therapeutics | Seed Round | - |
8/2021 | Beckley Psytech | Series B | 0 |
6/2021 | NanoPsy | Seed Round | 0 |
Name | Price |
---|
Name | Size | Announced Date |
---|